Nociscan is Aclarion’s augmented intelligence platform that measures disc health biomarkers and aims to help physicians identify the location of chronic back pain. The partnership will give surgeons one platform to access data.
“Evolving spinal technologies through innovation requires discipline, time, know-how and resources,” Pat Miles, CEO of Alphatec, said in the release. “This partnership with Aclarion reflects our belief in the importance of biochemical markers within the treatment paradigm. Nociscan is exactly the type of innovation that can advance our shared goal of integrating and advancing technologies that improve the predictability and reproducibility of spine care.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
